KR20080004581A - 불안 관련 장애의 치료 방법 - Google Patents

불안 관련 장애의 치료 방법 Download PDF

Info

Publication number
KR20080004581A
KR20080004581A KR1020077025774A KR20077025774A KR20080004581A KR 20080004581 A KR20080004581 A KR 20080004581A KR 1020077025774 A KR1020077025774 A KR 1020077025774A KR 20077025774 A KR20077025774 A KR 20077025774A KR 20080004581 A KR20080004581 A KR 20080004581A
Authority
KR
South Korea
Prior art keywords
treatment
patient
gaba
day
anxiety
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020077025774A
Other languages
English (en)
Korean (ko)
Inventor
산제이 사브나니
도널드 웨슨
Original Assignee
하이디엄, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 하이디엄, 인크. filed Critical 하이디엄, 인크.
Publication of KR20080004581A publication Critical patent/KR20080004581A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
KR1020077025774A 2005-04-07 2006-04-07 불안 관련 장애의 치료 방법 Ceased KR20080004581A (ko)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US66903305P 2005-04-07 2005-04-07
US60/669,033 2005-04-07
US72901305P 2005-10-21 2005-10-21
US72897905P 2005-10-21 2005-10-21
US60/728,979 2005-10-21
US60/729,013 2005-10-21

Publications (1)

Publication Number Publication Date
KR20080004581A true KR20080004581A (ko) 2008-01-09

Family

ID=37087555

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020077025774A Ceased KR20080004581A (ko) 2005-04-07 2006-04-07 불안 관련 장애의 치료 방법
KR1020077025773A Ceased KR20080004580A (ko) 2005-04-07 2006-04-07 물질 남용 및 의존의 치료 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020077025773A Ceased KR20080004580A (ko) 2005-04-07 2006-04-07 물질 남용 및 의존의 치료 방법

Country Status (12)

Country Link
US (3) US20080207601A1 (https=)
EP (3) EP1868593A2 (https=)
JP (3) JP2008538748A (https=)
KR (2) KR20080004581A (https=)
AU (3) AU2006235318A1 (https=)
BR (2) BRPI0609744A2 (https=)
CA (3) CA2604887A1 (https=)
CR (2) CR9410A (https=)
IL (2) IL186447A0 (https=)
MX (2) MX2007012353A (https=)
NO (2) NO20075155L (https=)
WO (3) WO2006110642A2 (https=)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050192271A1 (en) 2003-07-15 2005-09-01 Hythiam, Inc. Use of selective chloride channel modulators to treat alcohol and/or stimulant substance abuse
JP2008538748A (ja) * 2005-04-07 2008-11-06 ハイシアム， インコーポレイテッド 不安、物質乱用及び依存の予防のための改良型方法及び組成物
US20090269795A1 (en) * 2007-03-09 2009-10-29 The Research Foundation Of State University Of New York Mutant alpha4betadelta GABAA receptor and methods of treating anxiety or irritability
EP2164324B1 (en) * 2007-06-15 2014-08-13 University Of Florida Research Foundation Therapeutic compounds
US8486448B2 (en) 2007-12-17 2013-07-16 Paladin Labs Inc. Misuse preventative, controlled release formulation
ITRM20080436A1 (it) * 2008-08-06 2010-02-07 Francesco Marrosu Uso della finasteride e di altre sostanze inibenti l'enzima 5-a-reduttasi per la prevenzione e la cura dei disturbi dell'impulso e dell'aggressivita'
TWI541246B (zh) 2008-12-08 2016-07-11 歐陸斯迪公司 二氫羥戊甲嗎啡
ES2509497T3 (es) 2008-12-16 2014-10-17 Paladin Labs Inc. Formulación de liberación controlada para evitar un uso indebido
US9283212B2 (en) * 2009-02-20 2016-03-15 Palmaya Pty Ltd Pharmaceutical preparation and delivery system
WO2011073985A1 (en) * 2009-12-14 2011-06-23 Coeruleus Ltd. Compositions and methods of counteracting residual sedative effects of sleep/ hypnotic drugs
CA2785056A1 (en) 2009-12-22 2011-07-21 Pondera Biotechnologies, LLC Methods and compositions for treating distress dysfunction and enhancing safety and efficacy of specific medications
US20160120877A1 (en) * 2010-07-16 2016-05-05 James S Rowe Pharmaceutical compositions for sustained delivery of benzodiazepine antagonists
US8968722B2 (en) * 2010-12-29 2015-03-03 Mead Johnson Nutrition Company Milk-based nutritional compositions containing lactoferrin and uses thereof
WO2013043985A1 (en) 2011-09-23 2013-03-28 The Regents Of The University Of California Edible oils to enhance delivery of orally administered steroids
EP2806877B2 (en) 2012-01-23 2025-01-29 Sage Therapeutics, Inc. Neuroactive steroid formulations comprising a complex of allopregnanolone and sulfobutyl ether beta-cyclodextrin
CA2882708A1 (en) 2012-08-21 2014-02-27 Sage Therapeutics, Inc. Methods of treating epilepsy or status epilepticus
AU2013352141B2 (en) 2012-11-30 2018-04-05 The Regents Of The University Of California Anticonvulsant activity of steroids
HUE039057T2 (hu) * 2012-12-18 2018-12-28 Univ Washington Kezelési eljárásokban alkalmazható neuroaktív 19-alkoxi-17-szubsztituált szteroidok
GB201309654D0 (en) 2013-05-30 2013-07-17 Euro Celtique Sa Method
WO2015200766A2 (en) * 2014-06-26 2015-12-30 The Johns Hopkins University Peripherally restricted gaba positive allosteric modulators for the treatment of irritable bowel syndrome and other ailments of the peripheral nervous system
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
KR20240157128A (ko) 2016-03-08 2024-10-31 세이지 테라퓨틱스, 인크. 신경활성 스테로이드, 조성물, 및 그의 용도
US20180050005A1 (en) * 2016-08-16 2018-02-22 Janssen Pharmaceutica Nv Concentrated Solution of 17-Hydroxydocosahexaenoic Acid
RS67063B1 (sr) * 2017-01-09 2025-08-29 Relmada Therapeutics Inc Injektabilne suspenzije
GB201704909D0 (en) 2017-03-28 2017-05-10 Ldn Pharma Ltd Cancer therapy
WO2018178690A1 (en) * 2017-03-28 2018-10-04 LDN Pharma Limited An agent that increases the expression of the bcl2-associated agonist of cell death for the treatment of cancer
KR101898814B1 (ko) 2017-09-07 2018-09-13 백창목 도어 개폐용 도어록
US11129803B2 (en) 2017-09-18 2021-09-28 SEN-JAM Pharmaceutical LLC Methods and compositions to inhibit tolerance to opioids
US20190083430A1 (en) * 2017-09-18 2019-03-21 SEN-JAM Pharmaceutical LLC Methods and Compositions to Inhibit Symptoms Associated with Opioid Withdrawal
US12414956B2 (en) 2017-09-20 2025-09-16 Calista Capital, Llc Method for smoking cessation
WO2019060171A1 (en) * 2017-09-20 2019-03-28 Calista Capital, Llc METHOD FOR STOPPING TOBACCO
EP3482751A1 (en) * 2017-11-14 2019-05-15 LDN Pharma Limited Cancer treatment
JP2021519799A (ja) * 2018-04-05 2021-08-12 アサリナ ファーマ エーピーエス 物質離脱障害を治療するためのｇａｂａ−ａアンタゴニスト
JP2021521103A (ja) * 2018-04-06 2021-08-26 オービッド・セラピューティクス・インコーポレイテッドＯｖｉｄ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 物質使用障害の処置におけるガボキサドールの使用
WO2020061410A1 (en) 2018-09-20 2020-03-26 Ovid Therapeutics Inc. Use of gaboxadol for the treatment of tourette syndrome, tics and stuttering
WO2020181340A1 (en) * 2019-03-14 2020-09-17 Palmaya Pty Ltd Treatment of inflammatory diseases of the central nervous system
HRP20231735T1 (hr) * 2019-08-26 2024-03-15 Period Pill Bv Liječenje simptoma izazvanih menstrualnim ciklusom
US12233070B2 (en) * 2020-06-30 2025-02-25 University Of Mississippi Medical Center Methods for treating benzodiazepine misuse/use disorder
EP4251168A4 (en) * 2020-11-27 2024-11-06 Trexapharm Pty Ltd Compositions comprising flumazenil and naltrexone and methods for use thereof
US20220265601A1 (en) * 2021-02-10 2022-08-25 David Alan Heldreth, JR. Methods of use and formulations of allosteric modulators of the serotonin, dopamine and other receptor systems for medical, recreational, religious, research and other uses.
US12396981B2 (en) 2023-03-09 2025-08-26 William Shulman Methods of using DMT

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4034087A (en) * 1973-12-17 1977-07-05 The Regents Of The University Of Michigan Pharmaceutical composition and process of treatment
US4595684A (en) * 1985-08-16 1986-06-17 Ciba-Geigy Corporation Method of suppressing benzodiazepine induced sedation with 2-(p-methoxypenyl)-pyrazolo[4,3-c]quinolin-3(5H)-one or a salt thereof
US5175155A (en) * 1991-10-07 1992-12-29 Sterling Winthrop Inc. Win 49596-finasteride method of use and compositions
DE4344462C2 (de) * 1993-12-22 1996-02-01 Schering Ag Zusammensetzung für die Empfängnisverhütung
FR2719843B1 (fr) * 1994-05-10 1996-06-07 Synthelabo Dérivés de 5,6-dihydro-4h-imidazo [2',1':2,3] imidazo-[4,5,1-ij] quinoléine et de 4,5-dihydroimidazo [1,2-a] pyrrolo-[1,2,3-cd] benzimidazole, leur préparation et leur application en thérapeutique.
US5521181A (en) * 1995-01-27 1996-05-28 Abbott Laboratories Bicyclic substituted hexahydrobenz[e]isoindole α-1 adrenergic antagonists
IT1274481B (it) * 1995-05-12 1997-07-17 Indena Spa Composizioni farmaceutiche per il trattamento della alcol-dipendenza
WO1999010003A1 (en) * 1997-08-28 1999-03-04 Janus Pharmaceuticals, Inc. Androgen activity antagonists as therapies for anorexia, anorexia nervosa, and disorders characterized by a pathologically underweight condition
US6632447B1 (en) * 1998-05-07 2003-10-14 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
AU4100699A (en) 1998-05-28 1999-12-13 Sepracor, Inc. Compositions and methods employing r(-) fluoxetine and other active ingredients
EP1212051A4 (en) * 1999-08-27 2004-03-31 Merck & Co Inc METHOD FOR TREATING OR PREVENTING CHEMICAL PROSTATITIS OR CHRONIC POOL PAIN
US20020173495A1 (en) * 2000-08-24 2002-11-21 Dalton James T. Selective androgen receptor modulators and methods of use thereof
KR100712570B1 (ko) * 2001-01-17 2007-05-02 하이디엄, 인크. 알콜 의존성 치료약의 제조에서 플루마제닐의 용도
CA2436511C (en) * 2001-02-15 2009-08-04 Juan Jose Legarda Ibanez Use of flumazenil to produce a medicament for the treatment of cocaine dependency
GB0311859D0 (en) * 2003-05-22 2003-06-25 Merck Sharp & Dohme Therapeutic agents
PL1691811T3 (pl) * 2003-12-11 2014-12-31 Sunovion Pharmaceuticals Inc Skojarzenie leku uspokajającego i modulatora neuroprzekaźnikowego oraz sposoby poprawy jakości snu i leczenia depresji
JP2008538748A (ja) * 2005-04-07 2008-11-06 ハイシアム， インコーポレイテッド 不安、物質乱用及び依存の予防のための改良型方法及び組成物

Also Published As

Publication number Publication date
JP2008538748A (ja) 2008-11-06
CR9410A (es) 2008-02-21
WO2006110557A2 (en) 2006-10-19
CA2603519A1 (en) 2006-10-19
AU2006235318A1 (en) 2006-10-19
US8012958B2 (en) 2011-09-06
EP1868432A4 (en) 2009-11-04
WO2006110642A3 (en) 2009-04-23
EP1868432A2 (en) 2007-12-26
EP1901727A2 (en) 2008-03-26
NO20075155L (no) 2008-01-07
US20080207601A1 (en) 2008-08-28
JP2008535850A (ja) 2008-09-04
KR20080004580A (ko) 2008-01-09
US20080280885A1 (en) 2008-11-13
AU2006235257A1 (en) 2006-10-19
BRPI0610693A2 (pt) 2016-11-22
IL186447A0 (en) 2008-08-07
IL186450A0 (en) 2008-01-20
WO2006110580A3 (en) 2007-08-16
WO2006110557A3 (en) 2009-04-16
CR9413A (es) 2008-01-21
EP1868593A2 (en) 2007-12-26
WO2006110642A2 (en) 2006-10-19
CA2604887A1 (en) 2006-10-19
WO2006110580A2 (en) 2006-10-19
EP1901727A4 (en) 2009-11-11
JP2008535852A (ja) 2008-09-04
MX2007012355A (es) 2008-01-16
CA2603533A1 (en) 2006-10-19
US20080255097A1 (en) 2008-10-16
MX2007012353A (es) 2008-01-16
NO20075161L (no) 2008-01-07
BRPI0609744A2 (pt) 2010-04-27
AU2006235234A1 (en) 2006-10-19
AU2006235257B2 (en) 2010-11-04

Similar Documents

Publication Publication Date Title
US8012958B2 (en) Methods for treating anxiety related disorders
de Vries et al. Tetrahydrocannabinol does not reduce pain in patients with chronic abdominal pain in a phase 2 placebo-controlled study
CN112423789A (zh) 用于治疗抑郁症的艾司氯胺酮
KR20030025902A (ko) 덱스트로메토르판 및 옥시다제 억제제의 환자의 마약 및항진정제의 중단을 위한 용도
US20220023316A1 (en) Methods for the treatment of depression
ZA200903527B (en) Pharmaceutical combinations comprising testosterone in the treatment of female sexual dysfunction
PT1374952E (pt) Utilização de flumazenil no desenvolvimento de um fármaco para o tratamento da dependência do alcoól
AU2002231811B2 (en) Use of flumazenil to produce a medicament for the treatment of cocaine dependency
Dar et al. Overview of substance use disorder and available treatments
CN101272683A (zh) 治疗与焦虑有关疾病的方法
Catalano et al. Drug Therapy for Depression and Anxiety
Sinclair Drugs for alcohol dependence
Ciraulo et al. The pharmacology of nonalcohol sedative hypnotics
AU2006246490B8 (en) Use of flumazenil in developing a drug for the treatment of alcohol dependence
AU2006200922A1 (en) Use of flumazenil to produce a medicament for the treatment of cocaine dependency

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20071106

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20080220

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20100127

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20100406

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20100127

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I